Scientific Papers and Abstracts
The Journal of Molecular Medicine: August 2011
Paper: Non-redox-active lipoate derivatives disrupt cancer cell mitochondrial metabolism and are potent anti-cancer agents in vivo
Case Study and Case Report: 2011
Case study: Long-Term Stable Disease of Stage IV Pancreatic Neuroendocrine Tumors and Without Significant Adverse Effect by CPI-613, an Investigational Novel Anti-Cancer Agent
ASCO: 2011
Poster: Altered mitochondrial metabolism as a target in acute myeloid leukemia
ASCO: 2010
Abstract: Phase I trial of CPI-613, a lipoic acid analog, and gemcitabine in patients with advanced solid tumors
